Directorate Change

RNS Number : 2878T
Yourgene Health PLC
17 March 2023
 

Yourgene Health plc

("Yourgene", the "Group" or the "Company")

 

Directorate Change

Appointment of Interim Chief Financial Officer

 

Manchester , UK - 17 March 2023: Yourgene (AIM: YGEN), a leading international molecular diagnostic group, a nnounces that it has agreed that Barry Hextall, Chief Financial Officer ("CFO"), will step down from his role as a director to pursue other opportunities with immediate effect.

 

Barry, who has been with the Company for eight years, will provide an orderly handover over the next six months and will remain as Company Secretary until a full-time successor is appointed. Peter Charles, an experienced Interim CFO with broad cross sector experience, will take on the CFO role on a short-term basis, in a non-Board capacity. The process of recruiting a full-time CFO will begin immediately and it is expected to conclude in time for the full-time CFO to benefit from the agreed handover period.

 

Dr John Brown, Non-Executive Chairman, commented: "I would like to extend the Board's thanks to Barry for his contribution to Yourgene Health over the last eight years and his willingness to support an orderly handover. We wish him the very best for the future and look forward to updating shareholders further in due course."

 

This announcement contains inside information for the purposes of the UK Market Abuse Regulation. The Directors of the Company take responsibility for this announcement.

 

 

Yourgene Health plc

Lyn Rees, Chief Executive Officer

Tel: +44 (0)161 669 8122

investors@yourgenehealth.com

Joanne Cross, Director of Marketing




Cairn Financial Advisers LLP (NOMAD)

Tel: +44 (0)20 7213 0880

Liam Murray / Ludovico Lazzaretti


 


Singer Capital Markets (Corporate Broker)

Tel: +44 (0)20 7496 3000

Aubrey Powell / Tom Salvesen / George Tzimas




Walbrook PR Ltd (Media and Investor Relations)

Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com

Paul McManus / Alice Woodings / Lianne Applegarth

Mob: 07980 541 893 / 07407 804 654 / 07584 391 303 



 

About Yourgene Health

 

Yourgene Health is an international molecular diagnostics group which develops integrated genomic technologies and services enabling precision medicine. The group works in partnership with global leaders in DNA technology to advance diagnostic science. 

 

Yourgene primarily develops, manufactures, and commercialises simple and accurate molecular diagnostic solutions, for reproductive health, precision medicine and now infectious diseases. The Group's flagship products include non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, and a recent extension into the oncology space with DPYD genotyping.

 

The launch of Yourgene Genomic Services has enabled Yourgene to offer a global laboratory service network equipped to be a full life-cycle partner for clinical, research and pharmaceutical organisations to support partners at the preclinical, clinical, and post-market stages to develop, manufacture, obtain regulatory approval and commercialise new products and services. In addition, Yourgene Genomic Services offers an NIPT and high throughput COVID testing service.

 

In August 2020, Yourgene acquired Coastal Genomics , Inc., a sample preparation technology company based in Vancouver, Canada, enabling the Company to extend its offering and IP portfolio in the DNA sample preparation sector. The acquisition increased Yourgene's geographical penetration into the US and Canada, supplementing existing coverage in the UK, Europe, MEA and Asia.

 

Yourgene Health is headquartered in Manchester, UK with offices in Taipei, Singapore, the US and Canada, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information visit https://yourgenehealth.com/ and follow us on twitter @Yourgene_Health.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOADZGMFLVKGFZM
UK 100

Latest directors dealings